Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate carcinoma : results of a multicenter clinical trial of 6 , 630 men
1 Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate carcinoma: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283-90. 2 Brewster SF, Kemple T, MacIver AG, Astley JP, Gingell JC. The Bristol prostate cancer pilot screening study-a 3 year follow up. Br J Urol 1994;74:556-8. 3 Rosen MA. Impact of prostate-specific antigen screening on the natural history of prostate cancer. Urology 1995;46:757-68. 4 McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;i:60-3. 5 Stricker HJ, Ruddock U, Wan J, Belville WD. Detection of non-palpable prostate cancer. A mathematical and laboratory model. BrJr Urol 1993;71: 43-6. 6 Haggman M, Nybacka 0, Nordin B, Busch C. Standardization of in vitro mapping with multiple core biopsies of total prostatectomy specimens: localization and prediction of tumour volume and grade. Br J Urol 1994;74:617-25. 7 Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. 7 Urol 1996;155:816-20. 8 Lerner SE, Seay TM, Blute ML, Bergstralph EJ, Barrett D, Zincke H. Prostate specific antigen detected prostate cancer (clinical stage TI c): an interim analysis. J Urol 1996;155:821-6. 9 Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumour extent of non-palpable (stage TIc) prostate cancer.JAMA 1994;271:368-74. 10 Bostwick DG. Prospective origins of prostate carcinoma. Cancer 1996;78: 330-55. 11 Jones EC, Young RH. The differential diagnosis of prostatic carcinoma. Am _ Clin Pathol 1994;101:48-68. 12 Epstein JI. The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Cancer 1996;78:350-5. 13 Simpson JG, Lessells AM, Burnett RA, Howatson SR, Lang S, Lee FD, et al. Observer variability in the histopathological assessment of prostatic needle biopsies [abstract]. Pathology International 1996;46(suppl 1):A8 10. 14 Bostwick DG, Qian J, Bergstralph E, Dundore P, Dugan J, Myers RP, Oesterling JE. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996;155:1361-7. 15 Peller PA, Young DC, Marmaduke DP, Marsh WL, Badalament RA. Sextant prostate biopsies. Cancer 1995;75:530-38. 16 Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA. Prediction of prostate cancer volume using prostate specific antigen levels, transrectal ultrasound and systematic sextant biopsies. Urology 1995;45:75-80. 17 Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995;153:1543-8. 18 Bostwick DG. Gleason grading of prostatic needle biopsies. Am Jf Surg Pathol 1994;18:796-803. 19 von Eschenbach AC, Brawer MK, di Sant 'Agnese PA, Humphrey PA, Mahran H, Murphy GP, et al. Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. Cancer 1996;78:372-5. 20 Katz AE, De Vries GM, Olsson CA, Benson MC, Swanton P, Ikeguchi EF, Buttyan R. Molecular staging of genitourinary malignancies. Urology 1996; 47:948-58. 21 Smith MR, Biggar S, Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostatic cells: implications for detection of micrometastases. Cancer Res 1995;55:2640-4.